How many insider trades does FilingIQ track for RANI?

FilingIQ tracks 137 Form 4 insider transactions for RANI (Rani Therapeutics Holdings, Inc.), covering filings from Jul 30, 2021 onwards. 6 of those were filed in the last 90 days.

Are RANI insiders net buyers or net sellers?

Across the full Form 4 history for RANI, 86 transactions (63%) were open-market purchases and 9 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RANI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RANI in?

Rani Therapeutics Holdings, Inc. (RANI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $139.82M.

RANI insider trading

NasdaqGM Healthcare

Rani Therapeutics Holdings, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

137

Last 90 days

Buys / sells

63% / 7%

Market cap

$139.82M

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Company website: www.ranitherapeutics.com

RANI insider activity at a glance

FilingIQ has scored 137 insider transactions for RANI since Jul 30, 2021. The most recent filing in our index is dated May 28, 2026.

Across the full history, 86 open-market purchases and 9 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RANI insider trades is 38.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RANI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,234

UNITED THERAPEUTICS Corp

APLS 277

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 187

Guardant Health, Inc.

BMY 182

BRISTOL MYERS SQUIBB CO

HOLX 142

HOLOGIC INC

ADPT 140

Adaptive Biotechnologies Corp

KNSA 139

Kiniksa Pharmaceuticals International, plc

Frequently asked

How many insider trades does FilingIQ track for RANI?: FilingIQ tracks 137 Form 4 insider transactions for RANI (Rani Therapeutics Holdings, Inc.), covering filings from Jul 30, 2021 onwards. 6 of those were filed in the last 90 days.
Are RANI insiders net buyers or net sellers?: Across the full Form 4 history for RANI, 86 transactions (63%) were open-market purchases and 9 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RANI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RANI in?: Rani Therapeutics Holdings, Inc. (RANI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $139.82M.

Methodology & sources

Every RANI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.